ProfileGDS5678 / 1451733_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 56% 55% 54% 64% 53% 53% 56% 54% 57% 55% 54% 54% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3577953
GSM967853U87-EV human glioblastoma xenograft - Control 23.4083256
GSM967854U87-EV human glioblastoma xenograft - Control 33.3629855
GSM967855U87-EV human glioblastoma xenograft - Control 43.2990754
GSM967856U87-EV human glioblastoma xenograft - Control 53.7836664
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3840353
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3798753
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3955156
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3196454
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4487657
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3682855
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3103554
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3514754
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3505655